IP Library Granted Patent US 8,048,664
Granted Patent B2
US 8,048,664 · App. 12/949,182 · Granted Nov 1, 2011

Polynucleotides encoding modified DNA cleavage enzymes and host cells therefor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,048,664
App. No.
12/949,182
Granted
Nov 1, 2011
Kind
B2
Abstract

Compositions and methods are provided that relate to a modified DNA cleaving enzyme having at least 35% amino acid sequence identity with T 7 Endo I. The modified enzyme includes two catalytic centers separated by a β-bridge where the β-bridge contains at least one mutation having an effect of altering enzyme cleavage activity compared to the unmodified enzyme. Activities associated with the modified DNA cleaving enzyme that can be modulated in different reaction conditions include at least one of: (a) non-sequence specific nicking activity; (b) cleaving the second strand of a duplex DNA at a preexisting nick site to produce a linear duplex with a single strand overhang; (c) non-sequence specific DNA cleavage; (d) cleaving DNA flanking a mismatch; and (e) cleavage at a cruciform structure in a DNA duplex.

Claims (4)

1. A composition, comprising: an isolated polynucleotide encoding a variant T7 Endo I polypeptie having endonuclease activity, wherein the variant T7 Endo I polypeptide comprises an amino acid sequence that differs from the amino acid sequence of its parent T7 Endo I polypeptide solely by one or more mutations in a β-bridge corresponding to amino acids 44-49 of SEQ ID NO: 12.

2. A vector comprising a polynucleotide encoding a variant T7 Endo I polypeptide having endonuclease activity, wherein the variant T7 Endo I polypeptide comprises an amino acid sequence that differs from the amino acid sequence of its parent T7 Endo I polypeptide solely by one or more mutations in a β-bridge corresponding to amino acids 44-49 of SEQ ID NO: 12.

3. A host cell containing a vector comprising a polynucleotide encoding a variant T7 Endo I polypeptide having endonuclease activity, wherein the variant T7 Endo I polypeptide comprises an amino acid sequence that differs from the amino acid sequence of its parent T7 Endo I polypeptide solely by one or more mutations in a β-bridge corresponding to amino acids 44-49 of SEQ ID NO: 12.

4. A kit comprising in one or more containers a composition comprising a polynucleotide encoding a variant T7 Endo I polypeptide having endonuclease activity, wherein the variant T7 Endo I polypeptide comprises an amino acid sequence that differs from the amino acid sequence of its parent T7 Endo I polypeptide solely by one or more mutations in a β-bridge corresponding to amino acids 44-49 of SEQ ID NO: 12.

Assignments (2)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Sep 27, 2023
From: NEW ENGLAND BIOLABS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 065044/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2023
From: GUAN, CHUDI; KUMAR, SANJAY; KUCERA, REBECCA
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 064564/0853 →